Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas (NCT03179930)
A Phase II Study of Pembrolizumab and Entinostat in Patients With Relapsed and Refractory Lymphomas
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to test any good and bad effects of the study drugs called Pembrolizumab and Entinostat when used in combination to treat lymphoma. This combination could shrink the lymphoma but it could also cause side effects. Researchers also hope to learn whether adding entinostat to pembrolizumab can be more effective for patients with lymphoma than either drug alone.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (19 items) and avoid the listed exclusions (28 items).
Location: Northwestern University (Data Collection Only) — Evanston, Illinois
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Diagnosed or treated for malignancy other than the indication under study except for
- Malignancy treated with curative intent and with no known active disease present for at least 2 years before the first dose of study treatment
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- Adequately treated cervical carcinoma in situ without evidence of disease
- History of Human Immunodeficiency Virus (HIV)
- Active Hepatitis B or C infection
- History of active TB (Bacillus Tuberculosis)
- Concurrent enrollment in another therapeutic investigational clinical study or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug
- Known CNS lymphoma involvement
- Any uncontrolled active systemic infection or any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator"s opinion, could compromise the subject"s safety, interfere with the absorption or metabolism of entinostat capsules, or put the study outcomes at undue risk.
- Any history of (non-infectious) pneumonitis that required steroids, evidence of interstitial lung disease or active, non- infectious pneumonitis
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (9 Sites)
- Northwestern University (Data Collection Only) — Evanston, Illinois
- Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
- Roswell Park Cancer Institute (Data Collection Only) — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering Nassau — Uniondale, New York
📞 Contact the Study Coordinator
Phone: (855) 692-6482
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lymphoma
- A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma — Aurora, Colorado
- Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy — Salt Lake City, Utah
- TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas — Palo Alto, California
- A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients — New York, New York
- Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma — Rochester, Minnesota
- A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — La Jolla, California
Explore by condition: All Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.